Nuvectis Pharma Inc 's Cash & cash equivalent grew by 534.96 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Nuvectis Pharma Inc 's Quick Ratio to 9.91, above Nuvectis Pharma inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 307 other companies have achieved higher Quick Ratio than Nuvectis Pharma Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1036 to 1547.

Explain Quick Ratio?
How much Cash & cash equivalents NVCT�s has?
What are NVCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NVCT/financial-strength

https://api.csimarket.com/api/v1/companies/NVCT/fundamentals

https://api.csimarket.com/api/v1/companies/NVCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NVCT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	23.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	297.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	9.91	Subscribe	Subscribe	Subscribe	Subscribe
NVCT's Total Ranking	# 1547	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	6.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	534.96 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 308
Healthcare Sector	# 540
Overall Market	# 1547

Quick Ratio Statistics
High	Average	Low
6.14	3.78	1.67
(Sep 30 2022)		(Jun 30 2026)

Financial Statements
Nuvectis Pharma Inc 's Current Liabilities	$ 14 Millions	Visit NVCT's Balance sheet
Nuvectis Pharma Inc 's Cash & cash equivalent	$ 141 Millions	Visit NVCT's Balance sheet
Source of NVCT's Sales		Visit NVCT's Sales by Geography

Cumulative Nuvectis Pharma Inc 's Quick Ratio

NVCT's Quick Ratio for the trailling 12 Months

NVCT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	32.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	98.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.23	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 593	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	92.04 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NVCT Financial Strength Comparisons >> Go to Compare NVCT Quick Ratio to its Competitors

News about Nuvectis Pharma inc Quick Ratio

Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

In a significant stride towards improving the treatment landscape for non-small cell lung cancer (NSCLC), Nuvectis Pharma has announced the publication of a research study conducted at the Lerner Research Institute, part of the Cleveland Clinic at Case Western Reserve University. The study highlights the potential of the combination of NXP900 and epidermal growth factor receptor (EGFR) inhibitors to enhance the efficacy of existing EGFR inhibitors in preclinical models of EGFR-mutated NSCLC. This research offers a ray of hope to patients suffering from this challenging form of lung cancer, as the effectiveness of current therapies is often hampered by resistance mechanisms that develop over time.NXP900, an investigational therapeutic agent, has showcased promising results in the preclinical stage. The combination therapy utilizing NXP900 along with traditional EGFR inhibitors could potentially overcome existing therapeutic limitations, helping to combat the resistance seen in many NSCLC patients. This research adds to the growing body of evidence supporting the advancement of combination therapies in oncology, particularly for cancers driven by specific genetic mutations.

On the trailing twelve months basis NVCT Cash & cash equivalent more than doubled by 297.01 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Nuvectis Pharma Inc 's Quick Ratio to 4.23, above NVCT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Nuvectis Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3010 to 3789.

Explain Quick Ratio?
How much Cash & cash equivalents NVCT�s has?
What are NVCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 432
Healthcare Sector	# 880
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.69	3.54	2.32
(Dec 31 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Erasca Inc	13.10	$ 643.696 Millions	$ 49.122 Millions

Date modified: 2026-11-05T10:38:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.